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Abstract  Interventional  radiology  is  involved  practically  at  each  stage  in  the  treatment  of
hepatocellular  carcinoma,  as  recommended  in  the  EASL-EORTC  guidelines.  It  is  even  becoming
more important  as  technological  advances  progress  and  as  its  long-term  efﬁcacy  is  assessed.
Used curatively,  thermoablation  can  obtain  ﬁve-year  survival  rates  of  40  to  70%,  with  a  survival
rate of  30%  at  10  years.  As  there  are  many  tools  available  in  order  to  be  used,  it  requires  a
thorough  pre-treatment  assessment  and  discussion  in  a  multidisciplinary  team  meeting.  Reg-
ular patient  reassessment  is  needed  in  order  to  be  able  to  adjust  treatment  because  of  the
complementarity  of  the  treatments  available  and  the  course  of  the  disease.© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Hepatocellular  carcinoma  (HCC)  is  the  6th  leading  cancer  in  the  world  by  incidence
(749,000  new  cases  annually)  and  the  number  of  cases  of  HCC  has  increased  regularly
over  the  last  20  years  in  all  countries.  Its  annual  incidence  in  France  was  12.1/100,000  in
2012  in  men  and  2.4/100,000  in  women  (INVS  2013  report  www.invs.sante.fr).  In 75  to  80%
of  cases,  HCC  develops  in  cirrhosis,  which  is  a pre-malignant  situation  and  contributes  to
the  prognosis  of  the  cancer  as  it  impacts  on  treatment  methods.  However,  the  number  of
cases  of  HCC  diagnosed  in  non-cirrhotic  patients  is  continually  increasing,  mostly  due  to
the  prevalence  of  steatohepatitis.
∗ Corresponding author. Department of Radiology, CHU d’Angers, 4, rue Larrey, 49933 Angers, France.
E-mail address: ChAube@chu-angers.fr (C. Aubé).
http://dx.doi.org/10.1016/j.diii.2015.04.008
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Radiofrequency ablation26  
The  mortality  rate,  which  is  directly  linked  to  screening
ates  in  at  risk  patients  and  the  treatment  measures  avail-
ble,  varies  greatly  between  countries.  Whilst  it  continues
o  increase  in  many  countries  it  appears  to  have  stabilized
n  France  over  the  last  few  years  [1],  (www.invs.sante.fr).
However,  the  mortality  rate  from  hepatocellular  carci-
oma  remains  very  high  and  is  the  3rd  leading  cause  of
ancer  deaths  throughout  the  world.  The  mismatch  between
he  incidence  of  the  cancer  and  its  mortality  rate  highlights
he  importance  of  advances  that  still  need  to  be  made  in  its
iagnosis  and  treatment.
Treatments  are  currently  divided  somewhat  arbitrarily
nto  curative  therapies  which  include  liver  transplantation,
urgical  excision  and  percutaneous  ablation  methods  and
reatments  deemed  non-curative  or  ‘‘palliative’’,  which
nclude  chemoembolization,  systemic  therapies  (sorafenib)
nd,  currently  under  assessment,  radioembolization.  The
urvival  results  obtained  in  these  two  treatment  groups  are
xtremely  different.  If  curative  therapy  can  be  given,  the
-year  survival  rate  is  estimated  to  be  40  to  70%  whereas
ith  palliative  treatment,  the  corresponding  ﬁgure  is  only
0  to  20%  [2].  In  the  best  series,  the  proportion  of  patients
uitable  for  curative  treatment  is  no  greater  than  30  to
0%.  A  study  of  practice  carried  out  in  France  in  2010  [3]
howed  that  only  20%  of  patients  were  suitable  for  cura-
ive  treatment  when  the  HCC  was  discovered.  It  is  currently
onsidered  that  screening  for  HCC  in  patients  suffering  from
ompensated  cirrhosis  using  six-monthly  ultrasound  [4]  can
iagnose  HCC  in  the  curative  stage  in  over  70%  of  cases  [2].
Regardless  of  the  stage  of  the  disease,  amongst  the  treat-
ents  offered  whether  curative  or  palliative,  treatments
tilising  interventional  radiology  account  for  a  large  propor-
ion  of  the  treatment  options.
It  is  therefore  important  for  both  interventional  radio-
ogists  and  other  practitioners  to  understand  the  options,
imitations  and  place  of  these  treatments  in  the  man-
gement  of  HCC.  It  is  important  to  understand  from  the
utset  that  these  treatments  are  not  exclusive  and  that  a
atient  must  not  remain  ‘‘closeted’’  within  a  single  type  of
reatment,  but  should  be  able  to  beneﬁt  from  the  comple-
entarity  of  the  various  treatment  options  available.  During
he  course  of  the  disease,  which  is  largely  inﬂuenced  by
he  initial  treatments,  the  various  therapeutic  options  can
e  used  alternately.  The  choice  of  the  most  appropriate
reatments  throughout  the  course  of  the  disease  requires
n  initial  staging  assessment  and  detailed  clinical  and  radio-
ogical  monitoring,  together  with  regular  discussion  of  these
atients  in  the  Multidisciplinary  Team  Meetings.  The  staging
ssessment  and  treatment  decision  should  not  be  made  by
 single  specialty  but  should  be  the  result  of  a  multidisci-
linary  collegiate  decision.
re-treatment assessment
he  reference  diagnostic  method  for  HCC  is  still  histology,
lthough  the  diagnosis  can  be  made  non-invasively  in  HCC
hen  imaging  appearances  (CT  and  MRI)  are  characteristic,
nder  certain  strict  technical  and  interpretation  conditions.
The  presence  of  underlying  cirrhosis  is  an  essential  pre-
equisite  to  a  non-invasive  diagnosis  of  HCC.  The  diagnosis
f  cirrhosis  can  easily  be  inferred  from  clinical,  laboratory
PR,  platelets,  serum  albumin,  blood  markers  of  ﬁbrosis),
R
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lastometric,  endoscopic  (esophageal  varices),  and  morpho-
ogical  criteria  (hepatic  dysmorphism  and  ultrasound  or  CT
igns  of  portal  hypertension).  If  patients  have  no  symptoms
f  cirrhosis,  a  biopsy  of  the  non-malignant  liver  is  essential
o  demonstrate  the  presence  of  cirrhosis.
In  cases  of  cirrhosis,  a  liver  nodule  measuring  over  10  mm
n  diameter  exhibiting  hypervascularization  in  the  arterial
hase  followed  by  washout  in  the  portal  or  late  phase  on
T  or  MRI  is  deemed  to  be  a  hepatocellular  carcinoma.  It
hould  be  noted  that  in  the  international  guidelines  (EASL-
AORTC  2012)  in  non-expert  centers,  suspect  nodules  from
0  to  20  mm  need  to  be  consistent  on  CT  and  MRI  in  order  to
onﬁrm  the  diagnosis.  In  all  other  situations  and  particularly
f  the  diagnosis  of  cirrhosis  is  not  certain,  a  needle  biopsy
hould  be  performed  [2]. Generally,  however,  the  merits  of
iopsy  in  the  future  will  probably  become  increasingly  to
easure  prognostic  and  predictive  biomarkers  for  response
o  treatment.
It  is  important  to  remember  that  the  positive  diagnosis  of
CC  is  not  sufﬁcient  in  itself  to  initiate  a  discussion  on  treat-
ent.  Various  morphological  factors  need  to  be  considered,
ncluding  the  type,  nodular  or  inﬁltrative,  the  number  of
esions,  their  size,  their  anatomical  relationships  and  loco-
egional  and  extra-hepatic  extension  (lungs,  adrenal  glands,
tc.).  All  of  these  factors  should  be  routinely  listed  in  the
adiological  investigation  report.  A  standard  report  for  the
iagnosis  and  staging  assessment  of  hepatocellular  carci-
oma  can  be  found  on  the  Société  franc¸aise  de  radiologie
ebsite  (http://www.sfrnet.org).
Morphological  imaging  data  should  be  combined  with  all
f  the  clinical  and  laboratory  ﬁndings.  It  is  important  to
nderstand  that  in  90%  of  cases,  this  cancerous  disease
ccurs  on  a  background  of  pre-existing  disease  (cirrhosis  or
evere  ﬁbrosis),  the  course  and  prognosis  of  which  need  to
e  considered  in  the  treatment  of  the  HCC.  The  clinical  and
aboratory  features  required  to  calculate  the  Child—Pugh
core,  extent  of  hepatocellular  impairment,  portal  hyper-
ension  and  performance  status  of  the  patient  need  to  be
nown  in  order  to  consider  the  treatment  strategy.
In  practice,  the  proposal  for  treatment  should  be  deter-
ined  in  an  MDT  based  on  the  three  criteria  of  tumor
xtension,  the  state  of  the  non-malignant  liver  and  the
atient’s  general  health.  There  is  currently  no  consensus
bout  the  prognostic  classiﬁcation.  The  BCLC  classiﬁcation
roduced  by  the  Barcelona  group  is  the  one  most  widely
sed  in  France  [5].  It  is  a  treatment  decision-making  aid,
hich  follows  an  algorithm  published  in  the  international
uidelines  [2]. The  treatment  decision,  however,  should  not
emain  strictly  bound  within  these  schemas  from  the  inter-
ational  guidelines  and  information  obtained  should  be  used
o  adapt  the  treatments  for  each  patient  and  to  choose  the
echniques  available  depending  on  their  expected  results
nd  limitations.
nterventional radiology techniques for
epatocellular carcinoma treatmentadiofrequency  (RF)  ablation  uses  the  principle  of  apply-
ng  an  electrical  current  of  approximately  400  to  450  KHz
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Figure 1. Seventy-year-old man with alcoholic cirrhosis, no longer drinking. Hepatocellular carcinoma in the very upper part of the
dome of the liver measuring approximately 25 mm in size. a: attachment of the upper internal part of the lesion with the diaphragm; b:
hydrodissection: peritoneal injection of 1.5 L of isotonic dextrose solution in order to completely detach the lesion from the diaphragm; c:
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through  an  applicator  (needle)  within  the  tumor.  The  ionic
agitation  produced  increases  temperature,  which  beyond
70◦ causes  tissue  coagulation  necrosis.  It  should  be  noted
that  the  electrical  conduction  around  the  needle  is  produced
over  a  diameter  of  approximately  1  cm  and  beyond  this  dis-
tance  conduction  is  mostly  thermal,  explaining  some  of  the
limitations  of  this  technique  [6].
There  are  two  major  application  techniques:  by  far,  the
widest  used  technique  is  monopolar  (which  uses  single,  mul-
tiple  (cluster)  or  deployable  needles)  and  the  multipolar
technique  (which  is  less  often  used  as  it  is  more  technically
complex).
The  current  indications  for  RF  are  a  small  number  of  HCC
tumors  (conventionally  less  than  3)  and  small  size  (3  cm).
Size  is  one  of  the  major  limitations  of  the  technique  as  in
order  to  maintain  a  safety  margin  of  0.5  or  1  cm,  a  4  or
5  cm  ablation  is  required  for  a  3  cm  tumor.  These  are  the
maximum  diameters  of  coagulation  necrosis,  which  can  be
achieved  with  a  monopolar  technique  in  a  single  applica-
tion  [7].  At  the  cost  of  inserting  several  needles  into  the
periphery  of  the  tumor,  multipolar  techniques  can  be  used
to  achieve  larger  ablations  (5—6  cm)  [8].
Repeated  monopolar  applications  to  the  same  tumor
make  control  of  necrosis  more  difﬁcult  although  there  are
other  technical  limitations  to  RF  [9,10].  The  heat  sink  effect,
due  to  the  proximity  of  a  large  vessel,  may  be  a  factor
responsible  for  residual  tumor  if  the  area  of  the  tumor  close
to  the  large  vessel  is  within  the  thermal  conduction  and  not
electrical  conduction  area.  Some  procedures  are  designed
to  counter  the  heat  sink  effect,  such  as  balloon  obstruction
o
b
l
[ature of the lesion;d: no persistent arterial enhancement following
f  a  suprahepatic  or  portal  vein  which  is  afﬁxed  to  the  tumor
r  clamping  the  portal  trunk  if  radiofrequency  is  performed
uring  open  surgery.  However,  removing  the  vasculariza-
ion  makes  it  very  difﬁcult  to  predict  the  coagulation  zone
btained.
Subcapsular  lesions  are  a conventional  limitation  to  RF
ecause  of  the  risks  of  bleeding  and  tumor  seeding  [11].
ultipolar  techniques  can  circumvent  this  difﬁculty  partly
sing  a  ‘‘no  touch’’  technique,  which  involves  placing  the
eedle  on  either  side  of  the  tumor  without  actually  pen-
trating  it  and  producing  the  ablation  between  the  two
eedles.  Another  limitation  is  the  proximity  of  the  tumor  to
he  gastrointestinal  tract,  which  carries  a risk  of  gastroin-
estinal  wall  necrosis.  Techniques  for  detaching  the  tumor
rom  the  gastrointestinal  tract  are  available  by  introduc-
ng  air  or  dextrose  solution  (hydrodissection)  [12].  Another
imiting  factor  is  proximity  of  the  diaphragm  but  here
gain  interpositioning  ﬂuid  (controlled  ascites)  can  circum-
ent  this  contraindication  (Fig.  1).  In  addition,  lack  of
isualization  of  the  lesions  on  unenhanced  imaging  (par-
icularly  when  visualized  only  in  the  arterial  phase)  or
ifﬁculty  accessing  the  lesions  is  still  real  limitations.  Here
gain,  ancillary  techniques  can  often  be  used  to  circum-
ent  these  limitations:  using  lipiodol  labelling  of  the  tumor
hrough  arteriography  with  injection  of  lipiodol  into  the
epatic  artery  can  visualize  the  tumor  for  longer  peri-
ds  of  time  on  CT  (Fig.  2).  Image  fusion  techniques  can
e  used  for  treatments  under  ultrasound  guidance  for  a
esion  only  visible  in  the  arterial  phases  on  CT  or  MRI
13].
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Figure 2. Sixty-seven year old woman. Past history of right lobe HCC treated with partial right hepatectomy. a: found to have a raised
alpha-fetoprotein during follow-up with a hypervascularized nodular structure in the lateral part of segment IV, not seen on ultrasound and
only visible ﬂeetingly in the arterial phase (arrow); b: arterial injection of chemolipiodol resulting in intense lipiodol uptake in the lesion
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blation. Satisfactory safety margin; e: no MRI recurrence at 2 year
Undoubtedly  the  main  contraindication  is  proximity  to
he  convergence  of  the  biliary  tract,  as  there  is  no  tech-
ique,  which  can  circumvent  this  difﬁculty.  This  carries  a
isk  of  biliary  tract  necrosis  at  the  convergence,  leading  to
ermanent  obstruction  with  bilateral  biliary  tract  dilation.
The  complications  of  these  techniques  also  include
ematomas  and  abscesses  in  the  coagulation  zone,  although
he  risk  of  large  vessel  thrombosis  is  low.  Segmental  biliary
ract  dilation  due  to  ischemic  necrosis  of  the  ducts  close
o  the  coagulation  zone  occurs  relatively  commonly  but  is
nconsequential.  In  a  recent  literature  review,  the  mortality
f  RF  destruction  of  HCC  was  reported  to  be  0.15%,  with  a
ajor  complication  rate  of  4.1%  [14].
Published  results  describe  5-year  survival  rates  of  40  to
0%  [15,16]  and  long-term  survival  rates  (10  years)  in  the
egion  of  30%  [17].  These  are  similar  to  results  obtained
rom  surgical  excision  but  are  associated  with  a  high  rate  of
iver  recurrence  of  approximately  73%  at  5  years  and  98.5%
t  10  years  [17].
Few  studies  have  compared  radiofrequency  ablation  to
urgical  excision.  The  study  by  Chen  et  al.  [18]  showed  no
ifference  in  terms  of  4-year  survival  and  the  study  reported
y  Huang  et  al.  [19]  showed  survival  to  be  superior  at  5  years
or  excision  surgery,  although  this  study  contained  consider-
ble  bias.  Finally,  the  meta-analysis  reported  by  Cho  Yun
u  et  al.  [20]  showed  no  signiﬁcant  difference  between  the
wo  techniques.  More  recently  a  study  by  Kang  et  al.  on
mall  nodules  (BCLC  0  and  A)  showed  no  difference  between
adiofrequency  ablation  and  surgical  excision  in  terms  of
-year  survival  [21].
The  factors  found  to  inﬂuence  results  are  relatively  con-
istent  in  the  various  studies  [22]:  size  over  3  cm,  number
f  lesions  treated,  alpha-fetoprotein  concentration  and  the
hild—Pugh  score.  We  have  recently  shown  in  studies,  which
ave  not  yet  been  published  that  the  use  of  multipolar
echniques  also  reduced  the  recurrence  rate.  This  supports
ndings  reported  by  Seror  et  al.,  which  showed  higher  lev-
ls  of  necrosis  in  explanted  liver  specimens  using  multipolar
ompared  to  monopolar  techniques  [23].Two  types  of  treatment  combinations  have  been  pro-
osed  with  radiofrequency  tumor  ablation  to  potentiate  its
ffects.  Hyperemia  around  the  lesion  and  stimulation  of  the
roduction  of  proangiogenic  substances,  such  as  VEGF  during
t
g
iCT guidance after lipiodol labeling with multipolar radiofrequency
F  form  the  bases  for  combining  targeted  therapies  or  using
ourse  of  chemoembolization.
Several  studies  have  been  conducted  with  a combination
f  chemoembolization  and  sorafenib.  These  have  improved
he  time  to  recurrence  although  none  have  shown  improved
urvival  [24].
Combination  of  radiofrequency  ablation  with  chemoem-
olization  appears  to  be  more  promising  and  several  studies
ncluding  a  recent  meta-analysis  have  shown  not  only  a  gain
n  recurrence  rate,  but  also  in  terms  of  survival  for  interme-
iary  HCC  [25—27].
icrowave tumor ablation
his  is  a  form  of  thermoablation  based  on  a similar  prin-
iple  to  that  of  radiofrequency  ablation  although  in  this
echnique,  the  frequency  of  the  electric  current  is  between
00  megaHz  and  2  gigaHz  depending  on  the  generator.  These
requencies  do  not  produce  ionic  agitation  but  rather  pro-
uce  bipolarization  of  water  molecules,  movement  of  which
auses  very  rapid  heating.  This  removes  some  of  the  limita-
ions  of  radiofrequency  ablation,  in  particular  the  problem
f  carbonization  around  the  radiofrequency  needle  when
emperatures  exceed  110◦.  Carbonization  forms  an  elec-
rical  insulator,  which  impedes  electrical  conduction.  This
ffect  is  not  seen  with  microwave  ablation  and  the  tempera-
ures  achieved  are  therefore  considerably  higher.  Electrical
onduction  is  also  greater  (over  a  radius  of  approximately
 cm).  As  the  temperatures  close  to  the  needle  are  higher,
hermal  conduction  is  theoretically  greater.  These  advan-
ages  are  encumbered  by  disadvantages,  including  poor
ontrol  of  thermal  conduction  and  more  difﬁcult  control  of
ower  [28—30].
At  present,  the  potential  clinical  advantage  of  the  tech-
ique  is  the  speed  at  which  the  ablation  can  occur  (for  a
 cm  tumor,  coagulation  necrosis  is  obtained  by  microwave
n  approximately  5  minutes  compared  to  15  to  20  minutes
or  conventional  monopolar  radiofrequency  ablation).  The
educed  sensitivity  of  large  vessels  to  cooling  is  another
heoretical  advantage  as  the  electrical  conduction  zone  is
reater.
In  terms  of  results,  there  are  no  differences  published
n  the  literature  between  radiofrequency  and  microwave
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ablation  techniques  [31,32].  Microwave  ablation  has  the
same  limitations  and  contraindications  to  radiofrequency
ablation  although  it  probably  carries  a  higher  risk  of  damage
to  adjacent  organs  because  of  the  very  high  temperatures
achieved.
Electroporation
Electroporation  is  not  a  thermoablation  technique.  It
involves  the  application  of  high  voltage  electrical  pulses
(1000  to  2000  V),  which  are  very  short  and  damage  cellu-
lar  membrane  permeability.  This  change  in  permeability  is
initially  reversible  and  was  used  in  the  1990s  to  potentiate
the  effect  of  chemotherapy  (electrochemotherapy).  How-
ever,  above  a  speciﬁc  electrical  pulse  repetition  frequency,
the  damage  to  permeability  becomes  irreversible  and  leads
to  cell  apoptosis.  Cell  death  is  therefore  gradual,  and  is
not  associated  with  the  effects  of  necrosis,  inﬂammation
or  ﬁbrous  scarring  [33].  The  major  merits  of  this  technique
are  that  they  preserve  the  vascular  and  biliary  structures,
explained  mostly  by  the  high  collagen  ﬁber  content  of
these  structures,  which  are  not  affected  by  electroporation
effects.  Clinically,  therefore,  irreversible  electroporation
can  be  used  to  treat  tumors  close  to  the  biliary  tract  or  blood
vessels,  which  until  that  point  were  not  accessible  to  per-
cutaneous  radiofrequency  or  microwave  therapies  without
carrying  a  risk  of  serious  biliary  or  vascular  complications.
The  ﬁrst  electroporation  series  in  human  beings  was
reported  in  2011  by  Thomson  et  al.  [34].  Several  studies
since  then  have  shown  the  technique  to  be  feasible  with
a  similar  complication  rate  to  other  percutaneous  ablation
techniques  and  a  high  technical  success  rate  with  complete
ablation  rates  of  over  95%  [35].
The  technique,  however,  is  still  subject  to  numerous  lim-
itations,  particularly  technical  ones.  Several  needles  (2  to
6)  need  to  be  inserted  along  parallel  paths  with  fairly  strict
observation  of  the  distances  between  the  needles  (2.2  cm).
Application  of  electrical  pulses  requires  general  anaesthe-
sia  with  curarization  and  synchronization  of  the  pulses  with
cardiac  function.
Whilst  the  technique  appears  to  have  signiﬁcant  limita-
tions,  it  can  however  be  used  to  treat  patients  in  whom
other  ablation  techniques  are  not  possible  despite  having
small  tumors.
There  are  currently  no  large  series  in  hepatocellular  car-
cinoma,  although  the  method  merits  being  considered.
Chemoembolization
Chemoembolization  involves  injecting  a  cytotoxic  agent
(usually  doxorubicin)  bound  to  a  vector  into  the  hepatic
artery  and  then  carrying  out  arterial  embolization.  The
effectiveness  of  this  technique  is  due  to  the  fact  that
hepatocellular  carcinoma  is  vascularized  mostly  through  the
hepatic  artery  system,  unlike  the  unaffected  liver,  which  is
supplied  mostly  from  the  portal  venous  network.  The  aim  of
embolization  is  to  create  ischemic  cellular  necrosis,  potenti-
ate  the  action  of  the  cytotoxic  agent  and  slow  arterial  blood
ﬂow  to  increase  the  contact  time  between  the  cytotoxic
agent  and  the  tumor.  However,  the  beneﬁt  of  combining
a  cytotoxic  agent  with  embolization  remains  controversial.
It  is  likely  that  the  effectiveness  of  the  technique  is  due
r
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ostly  to  the  ischemia-producing  potential  of  emboliza-
ion.  Chemoembolization  techniques,  however,  vary  greatly
etween  centers  and  have  changed  over  time.  The  conven-
ional  technique  uses  a  mixture  of  lipiodol  and  a  cytotoxic
gent.  Lipiodol  is  used  as  the  vector  to  carry  the  cytotoxic
gent  to  the  tumor  by  binding  preferentially  to  tumor  cells
nd  passing  through  peribiliary  spaces  to  the  portal  system
36]. This  enables  a dual  arterial  and  portal  approach  to  the
umor.  With  this  technique,  the  embolizing  agent  may  be
emporary  (Curaspon)  or  permanent  (particles).  The  other
ajor  technique  involves  direct  use  of  particles  laden  with
he  cytotoxic  agent,  which  offer  more  gradual  release  with
ess  of  the  drug  passing  into  the  systemic  circulation  [37,38].
hilst  this  second  technique  has  been  shown  to  be  beneﬁ-
ial  in  terms  of  tolerability,  particularly  in  Child  B  patients,
t  has  not  been  found  to  produce  any  actual  gain  in  terms  of
urvival  [39].
The  technique  is  changing  towards  greater  selectivity  of
reatment,  optimally  targeting  only  the  tumor(s)  or  segment
ontaining  the  tumor.  The  selectivity  of  this  treatment  com-
ared  to  hemi-hepatic  therapy  (right  lobe/left  lobe  of  liver)
mproves  tolerability  and  tumor  response,  although  again  no
hange  in  survival  has  been  found  [40].  A  trend  is  also  devel-
ping  towards  using  smaller  embolization  particles  (100  to
00  microns)  in  order  to  increase  the  tumor  necrosis  [41,42].
his  reduction  in  microparticle  diameter  is  obviously  only
ossible  if  the  treatment  is  selective.  Finally,  the  use  of
rugs,  which  are  more  effective  than  doxorubicin  on  HCC,
ay  be  factor  contributing  to  greater  efﬁcacy.  Idarubicin
as  been  shown  to  be  a  potentially  useful  cytotoxic  agent
43].
The  survival  results  from  chemoembolization  are  still
ebated  widely  in  the  literature.  The  current  use  of
hemoembolization  is  based  on  one  positive  study  [44],  and
n  particular  on  a  meta-analysis  [45]. The  median  survival
ollowing  lipiodolated  chemoembolization  in  these  studies
as  20  months  although  more  negative  studies  are  regularly
eing  published  [46]. The  major  problem  appears  to  be  with
atient  selection.
The  main  limitations  and  complications  of  chemoem-
olization  are  hepatocellular  impairment  and  potentially
orsening  pre-existing  impairment,  which  limits  its  use  to
atients  with  preserved  hepatic  function  (Child—Pugh  score
 or  B),  without  invasion  of  the  portal  trunk.  This  type
f  contraindication  is  of  course  be  counterbalanced  by  the
ltraselective  nature  of  the  treatment.
As  for  the  technique  itself,  the  morbidity  rates  of
hemoembolization  vary  greatly  in  the  literature.  They
epend  on  the  extent  of  the  embolization,  selectivity  of
reatment  and  the  type  of  embolizing  agent  used.  The  post-
hemoembolization  syndrome,  which  is  a  combination  of
ain  and  fever  lasting  approximately  48  hours,  is  almost
lways  seen.  Expected  and  potentially  serious  complications
nclude  worsening  of  hepatocellular  impairment  and  decom-
ensation  of  cirrhosis.  Locally,  tumor  necrosis  and  abscess
ormation  may  occur.  The  incidence  of  severe  complications
as  reported  to  be  5.6%  (range  0—50%)  with  a  mortality  rate
anging  from  0%  to  10%  in  a  recent  literature  review  on  18
andomized  studies  [47].
Conversely,  treatment  of  diffuse  HCC,  even  with  small
odules,  which  requires  the  entire  the  liver  to  be  treated
eeds  to  be  carefully  considered  as  its  possible  efﬁcacy  may
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e  counterbalanced  by  severe  destruction  of  non-malignant
iver  parenchyma  [48].  Similarly,  treatment  of  diffuse  inﬁl-
rated  non-hypervascularized  tumors  remains  a  subject  of
ebate.  Recent  studies,  however,  show  that  chemoem-
olization  of  this  type  of  tumor  is  beneﬁcial  in  terms  of
urvival  with  a  low  complication  rate,  provided  that  patients
re  well  selected  [49].
The  frequency  with  which  courses  are  repeated  is  not
learly  deﬁned.  In  view  of  the  aggressive  effect  of  treatment
n  the  arterial  network  and  non-malignant  parenchyma,
nternational  guidelines  are  tending  towards  recommen-
ing  treatment  based  on  the  results  obtained  from  the  ﬁrst
ourse.  Repeating  the  treatment  is  only  justiﬁed  if  a  large
mount  of  residual  tumor  is  present  after  the  ﬁrst  course
r  if  the  disease  progresses  [2].  Criteria  to  continue  or  stop
reatment  after  an  initial  course  of  chemoembolization  (ART
riteria)  have  recently  been  proposed  and  are  based  on  mea-
urement  of  the  ALT,  the  Child—Pugh  score  and  the  tumor
esponse  after  a  course  of  chemoembolization  [50]. Recent
alidation  studies  for  this  score,  however,  have  been  nega-
ive  [50,51].
There  is  a  strong  rationale  to  combine  chemoemboliza-
ion  with  targeted  therapy.  As  a  result  of  the  ischemia,  which
t  produces,  chemoembolization  causes  overexpression  of
EGF  and  PDGFR-.  These  angiogenesis  factors  cause  a  local
ebound  effect  on  tumor  growth  and  an  increase  in  their  cir-
ulating  concentrations  can  promote  the  growth  of  new  HCC
umors  throughout  the  liver.
Many  studies  have  therefore  assessed  the  combination
f  chemoembolization  with  targeted  therapies,  such  as
orafenib,  bevacizumab,  endostatin  or  thalidomide  [52].
he  aim  of  most  of  these  studies  was  to  examine  toler-
bility  and  measure  the  time  to  progression,  which  was
ncreased  in  most  studies  from  an  average  of  4  to  9  months.
one,  however,  have  shown  beneﬁt  in  terms  of  survival  and
he  tolerability  of  targeted  therapies  remains  a  problem
52,53].
adioembolization
ike  chemoembolization,  radioembolization  is  based  on  the
rterial  vascularization  of  the  HCC  and  involves  injection
f  microspheres  labeled  with  a  radioisotope,  yttrium  90
90Y)  into  the  hepatic  artery.  This  enables  selective  inter-
al  radiotherapy  to  be  carried  out  on  liver  tumors  and  uses
ither  20  to  30  m  diameter  glass  or  resin  microspheres.
0Y  is  a  pure  beta  minus  (ˇ—)  emitter,  which  has  average
issue  penetration  of  2.5  mm  with  a  maximum  penetration
f  10  mm.  It  has  a  half-life  of  64.1  hours.  Following  injec-
ion  of  the  microspheres  into  the  hepatic  artery  and  once
hey  have  blocked  the  tumor  microvasculature,  emission
f  ˇ—  particles  by 90Y  irradiates  the  tumor.  In  view  of  the
ow  tissue  penetration  by  the  particles  emitted  by 90Y,  this
reatment  does  not  require  the  patient  to  be  isolated  in
 lead-lined  room  and  only  requires  limited  radioprotec-
ion  measures  after  the  treatment  has  been  delivered  [54].
imilarly,  irradiation  of  the  adjacent  non-malignant  liver  tis-
ue  around  the  tumors,  which  captured  the  microspheres,
s  low.
Preparatory  arteriography  is  required  before  injecting
he  radioactive  particles  into  the  right  or  left  hepatic  artery,
n
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epending  on  the  site  of  the  tumor  [55].  The  purpose  of
his  arteriography  is  to  determine  where  to  inject  the 90Y
abeled  microspheres  by  identifying  the  main  artery  sup-
lying  the  tumor  and  conﬁrming  that  there  are  no  arteries
rising  close  to  the  injection  site  which  could  lead  to  par-
icles  being  taken  up  by  extra-hepatic  organs,  primarily
he  gastrointestinal  tract.  As  such,  the  right  gastric  artery
sually  arises  from  the  common  hepatic  artery  or  the  ori-
in  of  the  left  hepatic  artery.  Preparatory  arteriography
an  preventatively  occlude  these  arteries  with  coils.  In
ddition,  if  the  tumor  is  vascularized  by  several  arteries,
ome  groups  propose  occlusion  of  some  of  these  arteries  to
‘monopediculize’’  the  tumor  so  that  there  is  only  a  sin-
le  artery  to  be  embolized.  Finally,  once  the  position  of  the
atheter  to  inject  the  microsphere  has  been  selected,  albu-
in  particles  labeled  with 99mTc  (99mTc-MAA)  are  injected,
ollowed  by  scintigraphy  (anterior  and  posterior  images  cen-
ered  on  the  liver  and  lungs  followed  by  SPECT-CT  images)
hich  ensure  that  the  tumor  is  correctly  targeted,  and  that
here  are  no  sites  of  extra-hepatic  gastrointestinal  hyperac-
ivity.  In  addition,  the  hepato-pulmonary  shunt  must  remain
ow,  with  the  objective  that  the  dose  being  delivered  to  the
ungs  is  less  than  30  Gy  per  treatment  session  and  a  maxi-
um  of  50  Gy  as  a  cumulative  dose  [56]  (Fig.  3).  If  carcinoma
s  present  in  both  lobes,  the  treatment  is  usually  delivered
equentially  with  one  injection  of 90Y  labeled  microspheres
o  each  lobe  of  the  liver,  on  each  occasion  preceded  by
reparatory  arteriography  and  scintigraphy  [55].  It  is  impor-
ant,  however,  to  keep  in  mind  the  fact  that  the 99mTc-MAA
articles  are  different  from  the  resin  or  glass  particles  used
n  radioembolization  and  that  they  behave  differently  in
he  arterial  blood  ﬂow.  The  distribution  of  the 90Y  labeled
articles  may  therefore  be  different.
Calculation  of  the  activity  of  the 90Y  labeled  microspheres
o  be  administered  varies  depending  on  the  type  of  par-
icle  used.  The  activity  calculation  for  resin  microspheres
s  usually  based  on  body  surface  area  and  the  percentage
f  tumor  invasion  whereas  the  calculation  of  activity  for
lass  microspheres  is  based  on  the  ‘‘Medical  Internal  Radia-
ion  Dose’’  (MIRD)  methodology  [57]. For  glass  microspheres,
ctivity  is  generally  calculated  to  obtain  a  dose  of  between
0  and  120  Gy  to  the  perfused  liver  [56]. Ideally,  extensive
rradiation  of  the  tumor  lesions  is  sought  at  the  same  time
aintaining  irradiation  of  the  non-malignant  parenchyma
elow  a  given  threshold.  In  this  context,  using  high  per-
ormance  tools  for  the  planned  dosimetry,  a recent  study
howed  ‘‘intensiﬁcation’’  of  treatment  and  administration
f  higher  doses  to  the  tumor  without  increasing  hepatic  tox-
city  [58].
Once  the 90Y  labeled  microspheres  have  been  adminis-
ered, 90Y  Bremsstrahlung  SPECT-CT  imaging  or  a 90Y  PET-CT
maging  (internal  pair  production  of 90Y)  is  performed  in
rder  to  ensure  that  the  spheres  are  correctly  distributed
59].
There  are  many  studies  ongoing  to  assess  the  efﬁcacy
f  this  new  treatment.  The  ﬁrst  reported  [60]  showed
edian  survival  of  24.4  months,  16.9  months  and  10  months
or  BCLCA,  BCLCB  and  BCLCC  patients,  respectively  in  whom
o  treatment  other  than  systemic  chemotherapy  was  possi-
le.  A  meta-analysis  of  14  studies  on  the  radioembolization
reatment  of  liver  tumors  showed  tumor  response  rates  for
CC  ranging  from  78  to  89%  [61].
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Figure 3. Seventy-seven year old patient with hepatocellular carcinoma on a background of cirrhosis, already treated by chemoemboliza-
tion. Tumor recurrence in segment IV. a: preparatory arteriography: large lesion blush representing the tumor in segment IV (solid arrow). A
small right gastric artery arising from the proximal left hepatic branch is seen (hollow arrow); b: Arteriography control showing the position
of the microcatheter in the branch of segment IV supplying the tumor and representing the injection site for 99mTc-MAA (solid arrow).
Coils seen in the embolized right gastric artery (hollow arrow); c: axial SPECT-CT image after injection of 99mTc-MAA: good distribution of
tracer in the tumor and no extra-hepatic uptake; d: scintigraphic images allowing the pulmonary shunt to be calculated using the geometric
mean method; e: axial SPECT-CT view after treatment following injection of SIR-sphere microspheres suggesting good tumor targeting and
correlating well with pre-treatment scintigraphy; f: axial CT image in the arterial phase after injection. Hypervascularized heterogeneous
HCC nodule in segment IV; g: follow-up axial CT image in the arterial phase 5 months after radioembolization showing a large reduction in
size of the lesion with no persistent enhancement (arrow).
a
iIn  parallel,  this  treatment  is  usually  well  tolerated,
better  than  chemoembolization  or  targeted  therapy.  The
post-embolization  syndrome  (nausea,  vomiting,  abdominal
pain  and  fever)  is  less  common  than  with  chemoem-
bolization.  Severe  complications  have  been  reported  for
accidental  embolization  of  non-hepatic  organs,  includ-
ing  gastrointestinal  ulceration,  pancreatitis,  cholecystitis
I
I
snd  radiation-induced  pneumonia  [62].  Cases  of  radiation-
nduced  hepatitis  have  been  described  [63].ndications
nterventional  radiology  is  involved  practically  at  each
tage  in  the  treatment  of  hepatocellular  carcinoma  as
632  C.  Aubé  et  al.
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aigure 4. Treatment strategy according to the BCLC classiﬁcat
epatology [2].
ecommended  in  the  EASL-EORTC  guidelines  (Fig.  4).  It  is
ven  becoming  more  important  as  technological  advances
rogress  with  the  long-term  assessment  of  its  efﬁcacy  [17].
Whilst  transplantation  remains  the  treatment,  which
chieves  the  best  survival  rate  for  BCLC  stage  A  patients,  it
s  only  available  for  a  small  number  of  patients.  The  drop  out
ate  from  the  transplant  list,  which  is  30%  at  1  year  for  HCC
64,65],  requires  a  bridge  treatment.  This  mostly  involves
nterventional  radiology.  Whilst  chemoembolization  has  long
een  the  treatment  of  choice,  despite  being  disputed  in
erms  of  efﬁcacy  [66],  percutaneous  ablation  is  taking  on
 greater  role  [64,67].
According  to  the  international  guidelines,  patients  with  a
ingle  ‘‘early’’  HCC  (BCLC  classiﬁcation  stage  0)  and  without
iver  dysfunction  or  severe  portal  hypertension  are  candi-
ates  for  excision  surgery.  In  routine  practice,  however,
here  is  still  a  question  about  its  use  compared  to  percuta-
eous  ablation  depending  on  the  site  of  the  tumor  (a  central
umor  requires  wide  excision  or,  compared  conversely,  to  a
ubcapsular  tumor  which  can  easily  be  resected  laparoscopi-
ally).  Percutaneous  ablation  is  therefore  tending  to  become
ffered  ﬁrst  line  for  small  tumors  by  many  groups,  surgery
eing  considered  if  a  percutaneous  approach  has  limitations
2,68,69].
In  patients  who  do  not  have  many  (less  than  3)  HCC  which
re  small  (size  under  3  cm),  percutaneous  tumor  destruc-
ion  is  the  method  of  choice.  At  present,  the  radiofrequency
blation  technique  is  preferred  for  this,  although  the  avail-
bility  of  multipolar  and  microwave  methods  should  allow
reatment  to  be  potentiated  by  choosing  the  appropriate
echnique.  It  has  become  possible  to  treat  multiple  tumors
ith  microwave  and  to  treat  a  lesion  lying  close  to  a  large
essel.  Larger  tumors  can  be  treated  using  the  multipolar
adiofrequency  technique.
a
o
wrom the EORTC and EASL guidelines published in the Journal of
Intermediary  stage  HCC  (stage  B)  accounts  for  a  large
roportion  of  HCC  at  the  time  of  diagnosis.  As  the  indica-
ions  for  the  chemoembolization  are  very  wide,  it  remains
he  most  commonly  used  treatment  for  HCC  (20  to  30%  of
atients  with  HCC).  According  to  international  guidelines,
hemoembolization  is  used  for  patients  with  intermediary
tage  (BCLC  B)  with  multifocal  tumors  or  tumors  which  are
oo  large  to  be  able  to  be  treated  curatively,  but  who  are
till  in  good  general  health  (performance  status  =  0),  with-
ut  portal  thrombosis  and  with  preserved  liver  function  (less
han  Child  B  7).  However,  this  is  the  most  heterogeneous
roup  of  patients  and  for  tumors  up  to  5  cm  in  size,  mul-
ipolar  radiofrequency  ablation,  whether  or  not  combined
ith  chemoembolization,  can  be  considered  and  appears  to
roduce  good  results  [70].  Conversely,  for  more  inﬁltrative
esions  or  in  patients  in  poor  general  health,  radioemboliza-
ion  may  represent  an  alternative.
For  targeted  therapies  (sorafenib)  represent  the  cur-
ent  standard  for  more  advanced  tumors  in  patients  whose
iver  function  is  still  satisfactory  (Child—Pugh  score  <  B7).  If
adioembolization  were  proven  from  the  randomized  stud-
es  [71], this  technique  will  become  an  alternative  to  the
ystemic  therapies  [72,73].
Whilst  the  main  principles  of  treatment  are  deﬁned  in
nternational  guidelines  (Fig.  4),  the  situation  is  not  set  in
tone  and  each  patient’s  case  should  be  discussed  in  light  of
he  available  options.  It  is  essential  to  offer  the  best  treat-
ent  at  a  given  time  in  the  course  of  the  disease  and  to
nderstand  the  options,  together  with  their  possibilities  and
imitations,  as  it  is  important  to  consider  how  the  treatments
re  used  in  succession  and  sequentially.  Patients  should  have
ccess  to  several  types  of  treatment  and  it  is  likely  that
ver  time  a  combination  of  the  various  treatment  options
ill  signiﬁcantly  increase  patient  survival.  As  an  example,
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Shon  et  al.  recently  showed  that  RF  treatment  of  residual
lesions  following  chemoembolization  could  achieve  higher
survival  rates  than  those  usually  seen  with  chemoemboliza-
tion  alone  [74].  The  10-year  survival  rate  reported  for  HCC
is  not  a  result  of  a  single  treatment  but  the  consequence  of
combining  all  of  the  treatment  options,  discussed  regularly
in  the  MDT.
Take-home  messages
• In  France,  only  20%  of  HCC  patients  are  discovered
at  a  stage  allowing  curative  treatment  to  be  offered.
• The  choice  of  treatment  for  HCC  should  be  made  in
a  multidisciplinary  team  meeting  after  the  imaging
staging  assessment  and  a  full  clinical  and  laboratory
assessment.
• Radiofrequency  tumor  ablation  can  achieve  10-year
survival  rates,  which  are  almost  equivalent  to  those
of  surgical  resection  for  tumors  under  30  mm  in  size.
• Chemoembolization  and  percutaneous  tumor
destruction  are  bridge  treatments  for  liver
transplantation.
• Radioembolization  is  a  technique  currently  being
assessed  which  main  gain  a  signiﬁcant  place  in  the
treatment  of  intermediary  and  advanced  HCC.
• The  various  treatments  are  complementary  and
should  be  adapted  throughout  the  course  of  the
disease.
Clinical case
A  69-year-old  man  with  metabolic  cirrhosis  was  referred  to
us  for  possible  treatment  of  hepatocellular  carcinoma.
The  patient  had  MR  imaging  examination  after  the
discovery  of  a  nodule  during  the  six-monthly  ultrasound
examination  (Fig.  5).
Questions
1.  Without  any  other  information,  what  treatment(s)  would
be  appropriate  for  this  patient?
A.  Transplantation
B.  Surgical  resection
C.  Tumor  destruction  by  monopolar  radiofrequency  abla-
tion
D.  Ultra  selective  chemoembolization  with  loaded  par-
ticlest in the arterial (a) and portal (b) phase.
E.  Sorafenib
.  What  additional  test  and  information  should  be  obtained
for  a  discussion  about  treatment?
A.  Chest  CT  scan
B.  Esophageal  endoscopy
C.  Tumor  biopsy
D.  The  portal-suprahepatic  gradient
E.  Measurement  of  plasma  bilirubin
.  The  patient  is  Child  stage  A  with  severe  portal  hyper-
tension  and  a  performance  status  =  0.  What  treatments
would  you  offer  in  the  multidisciplinary  team  meeting?
A.  Transplantation
B.  Surgical  resection
C.  Tumor  destruction  by  monopolar  radiofrequency  abla-
tion
D.  Microwave  tumor  destruction
E.  Selective  radioembolization
.  In  the  event  of  a single  recurrence  in  the  left  lobe
of  the  liver  15  mm  in  diameter  within  2  years  and  the
patient’s  laboratory  and  clinical  situation  is  unchanged,
what  treatment  options  would  you  consider?
A.  Transplantation.
B.  Salvage  surgery.
C.  Tumor  destruction  by  radiofrequency  ablation.
D.  Selective  chemoembolization  of  the  left  lobe  of  the
liver.
E.  Sorafenib.
nswers
 B,  C.
 A,  B,  E
 C,  D.
 C.
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